Back to BMY Overview
NYQ · Valuation Lab
BMY
Bristol-Myers Squibb Company
Last$63.63
Market cap130B
EV/EBITDA8.9x
Intrinsic value
$119.89
MoS +46.9% · Undervalued
Assuming 16.5% FCF margin and 5.7% Y1–5 growth.
Upside to price
EV (DCF)278.9B
Terminal share72%
Expected IV$118.44
Probability weights
Projected free cash flows
Stage FCF path with present values · terminal 72% of EV
PV of stage FCFs76.9B
PV of terminal value202B
Enterprise value278.9B
Net cash / (debt)-34B
Equity value244.9B
Intrinsic value / share$119.89
| Year | Revenue | FCF | PV | DF |
|---|---|---|---|---|
| Y1 | 52B | 8.6B | 8.1B | 94.3% |
| Y2 | 55B | 9.1B | 8.1B | 89.0% |
| Y3 | 58.1B | 9.6B | 8B | 84.0% |
| Y4 | 61.4B | 10.1B | 8B | 79.2% |
| Y5 | 64.9B | 10.7B | 8B | 74.7% |
| Y6 | 66.8B | 11B | 7.8B | 70.5% |
| Y7 | 68.7B | 11.3B | 7.5B | 66.5% |
| Y8 | 70.7B | 11.7B | 7.3B | 62.7% |
| Y9 | 72.8B | 12B | 7.1B | 59.2% |
| Y10 | 74.9B | 12.4B | 6.9B | 55.8% |
| Terminal | — | — | 202B | — |
Educational DCF model only — not financial advice. Terminal value and assumptions dominate results; verify filings and run your own diligence.